The drugmaker's profits were driven by lower taxes and an increase in product sales of newer drugs. » Read More
Rare disease drug maker Shire Plc said it was willing to recommend a sweetened offer from Japan's Takeda Pharmaceutical Co to shareholders. » Read More
New listing rules for Hong Kong's stock exchange may result in some new biotech listing applications coming as early as May, says Benson Wong of PwC Hong Kong. » Read More
Investors are looking for bigger tech names to list on Hong Kong's stock exchange under the new rules, says Irene Chu of KPMG China.
Charles Li of Hong Kong Exchanges and Clearing says access to capital is critical for highly-regulated companies developing drugs.
CNBC's Meg Tirrell reports on Shire and Takeda reaching a breakthrough in merger talks according to Reuters.
Drug developer Biogen reported a 11.4 percent rise in quarterly revenue as sales of key drugs Tecfidera and Spinraza climbed, albeit at a weaker-than-expected pace.
A Food and Drug Administration panel advised on Monday against a high dose of Lilly-Incyte's rheumatoid arthritis drug while voting in favor of the lower dose.
New York's attorney general said state tax authorities are entitled to first dibs on more than $480,000 out of the nearly $7.4 million Shkreli was ordered to forfeit as regulators reveal Shrkreli had agreed to be barred from the securities industry.
If you have leftover pain pills or other prescription drugs, you should get rid of them. Drugstore chains Walgreens and CVS Health are adding kiosks in some of their stores to make it easier.
Goldman Sachs upgrades Merck to buy from neutral.
German health-care group Fresenius said it had decided to pull out of its planned acquisition of Akorn after it found data integrity breaches at the U.S. generic drugmaker.
CNBC’s David Faber reports that Japanese drug company Takeda is increasing its proposal for Shire.
J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.
Drug manufacturers are using several schemes to "hamstring biosimilar competition," and FDA Commissioner Scott Gottlieb worries pharmacy benefit managers have been "complacent participants" in them.
Allergan will not bid for Shire, according to sources close to the company.
Jim Cramer hears from Revance Therapeutics co-founder, President and CEO Dan Browne about his biotechnology therapy that competes with Allergan's Botox.
Epidiolex would be the first drug on the market derived from the cannabis plant.
CNBC’s David Faber reports that pharma company Allergan will not follow through with a big on Shire, according to sources.
Get the best of CNBC in your inbox